Previous 10 |
home / stock / cspcy / cspcy news
Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group PR Newswire Obtains exclusive worldwide rights (outside Greater China ) to develop and...
Deals And Financings ACEA Biosciences, a San Diego company with R&D and manufacturing facilities in Hangzhou, will be acquired by Agilent (NYSE: A) for $250 million in cash (see story ). ACEA has developed the xCELLigence® cell therapy analysis device intended for academic and biop...
Profit Attributable To Shareholders Increased 41.1% to HK$1,853 Million Innovative Drug Business Continued to Deliver Strong Growth Common Generic Drug Business Increased Market Penetration Bulk Drug Business Kept Market ...
News, Short Squeeze, Breakout and More Instantly...
CSPC Pharmaceutical Group Ltd ADR Company Name:
CSPCY Stock Symbol:
OTCMKTS Market:
Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 PR Newswire Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refract...
Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 PR Newswire NEW YORK , April 26, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology comp...
Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC) PR Newswire CRB-701 (SYS6002) is designed for improved therapeutic index and to act on a broad range of Nectin-4 expressing tumors ...